Author is bullish on ImmunityBio (IBRX) citing ANKTIVA commercialization, 700% YoY revenue growth to ~$113M, Saudi approval in NSCLC, and the QUILT-2.005 BCG-naive trial.
IBRX — LONG The author argues IBRX's core value is the successful commercialization of ANKTIVA, with preliminary 2025 net product revenue of roughly $113 million (a 700% YoY increase) and Q4 2025 around $38.3 million showing accelerating adoption. The Saudi FDA's January 2026 accelerated approval of ANKTIVA in bladder cancer and NSCLC is framed as the first global solid-tumor approval, de-risking the platform for broader applications. The QUILT-2.005 BCG-naive trial, with enrollment ahead of schedule and expected completion Q2 2026, could expand the total addressable market by moving the drug to an earlier treatment line. The author states they have been stacking the position and are 'balls deep,' acknowledging binary risk via the joke about a mansion or a trailer.
The core value proposition for IBRX right now is the successful launch of ANKTIVA
This Reddit post, published January 16, 2026, features u/lulmagician discussing IBRX. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/lulmagician · Tickers: IBRX